Drug Discovery World

APRIL 30, 2024

The biggest growth driver for mRNA therapeutics came from the Covid-19 pandemic, when mRNA-based vaccines proved effective in treating SARS-CoV-2, and pharmaceutical companies such as Pfizer/BioNTech and Moderna were successful in bringing these treatments to market.

Therapies 130

Therapies RNA Vaccine Small Molecule 130

Drug Discovery World

NOVEMBER 8, 2023

Helmut Salih, MD, Professor for Translational Immunology, Medical Director, Clinical Collaboration Unit Translational Immunology, University Hospital Tuebingen and DKFZ Heidelberg, Germany; Co-Founder, TWYCE GmbH, on: ‘An optimised IgG-Based B7-H3xCD3 bispecific antibody for treatment of gastrointestinal cancers’. Claes Gustafsson, Ph.D,

Engineering 162

Engineering Protein Expression Therapies Science 162

Drug Discovery World

NOVEMBER 9, 2023

Sandra Ergueta-Carballo, PhD, Project Coordinator, University of Cambridge, on: ‘Advancing snake envenomation treatment: designing the next generation of antivenoms’. Lei Shi, PhD, Senior Vice President, R&D, Biointron Biological, on: ‘Accelerating early discovery through htp and high-speed antibody production’.

Engineering 130

Engineering Protein Production Therapies Science 130

The Pharma Data

JANUARY 13, 2021

Germany-based Cevec Pharmaceuticals GmbH signed a licensing agreement with Biogen for the use of its proprietary ELEVECTA Technology for the manufacturing of adeno-associated virus (AAV) vectors for gene therapy applications. The deal will provide Biogen the rights to use the technology across their portfolio of gene therapy products.

Licensing 52

Licensing Licensing Clinical Trials Vaccine 52